[Federal Register Volume 82, Number 242 (Tuesday, December 19, 2017)]
[Notices]
[Pages 60199-60200]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-27257]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-18-17AMP]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Evaluation of the SAMHSA Naloxone Education
and Distribution Program to the Office of Management and Budget (OMB)
for review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
July 17, 2017 to obtain comments from the public and affected agencies.
CDC did not receive comments related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to [email protected]. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide
written comments within 30 days of notice publication.
Proposed Project
Evaluation of the SAMHSA Naloxone Education and Distribution
Program--New--National Center for Injury Prevention and Control
(NCIPC), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Overdose deaths involving prescription opioids and heroin have
reached epidemic levels in the U.S. and continue to rise. To address
the prescription drug/opioid overdose crisis, the federal government
has recently allocated funding to improve access to treatment for
opioid use disorders, reduce opioid related deaths, and strengthen
prevention efforts. One program resulting from the federal government's
efforts to address the opioid crisis is the Substance Abuse and Mental
Health Services Agency (SAMHSA) Grants to Prevent Prescription Drug/
Opioid Overdose-Related Deaths. This proposed information collection
project will help evaluate this program.
Through this program, SAMHSA awarded funding to 12 states. The
funding is aimed at reducing the number of prescription drug/opioid
overdose-related deaths and adverse events among individuals 18 years
of
[[Page 60200]]
age and older through educating and training first responders and other
key community sectors on the prevention of prescription drug/opioid
overdose-related deaths, including the purchase and distribution of
naloxone. SAMHSA is funding the grant and CDC is responsible for
conducting the grantee evaluation.
The intended use of the resulting data is to increase CDC and
SAMHSA understanding of the scope and impact of the program on overdose
fatalities and how program effectiveness may vary among different sub-
populations and settings, and to increase knowledge of barriers and
facilitators to program implementation.
Researchers will use key informant interviews and focus groups with
participants in the activities enacted by the twelve state grant
recipients. Participants will include state administrators of the grant
and other PDO/Naloxone stakeholders including advisory council members,
first responders, social service providers, laypersons including end
users and their family and friend. All focus groups and interviews will
be analyzed through qualitative content analysis, including utilization
of a systematic coding scheme.
Total burden in hours for this collection is 381. There are no
costs to respondents other than their time. CDC requests a three-year
OMB approval to collect the necessary project-related information.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
PDO/Naloxone Advisory Committee Focus Group Discussion 140 1 1.5
Members and Grantees. Guide.
PDO/Naloxone Grantees................. Key Informant Interview 36 1 1
Guide for Grantees.
PDO/Naloxone Stakeholders and Partners Key Informant Interview 84 1 1
Guide for Partners.
PDO/Naloxone Laypersons............... Key Informant Interview 24 1 1
Guide for Laypersons.
All participants (PDO Naloxone Recruitment contact 284 1 5/60
grantees, advisory committee, script.
stakeholders and partners,
laypersons).
PDO/Naloxone Grantees................. Key Informant Selection 12 1 15/60
Tool.
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-27257 Filed 12-18-17; 8:45 am]
BILLING CODE 4163-18-P